Navigation Links
Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
Date:9/3/2014

otics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique
2. Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections
3. Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
4. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
5. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
6. Synthetic Biologics to Report Second Quarter 2014 Financial Results
7. Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
8. Global Synthetic Biology Market 2014-2018
9. Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
10. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
11. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... BALTIMORE , Aug. 31, 2015  For people ... may brighten their day. The biotechnology company, located in ... outlined one of the best potential therapies yet for ... paper entitled, " Correction of Down syndrome and Edwards ... the journal DNA Research . Elixirgen plans to ...
(Date:8/31/2015)... HAYWARD, Calif. and SHANGHAI ... Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, ... Phase 2 clinical study for its lead drug ... designed to treat drug-resistant bacteria such as MRSA ... safer and better tolerated therapeutic option than currently ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have acknowledged ... development approval process. Thus, innovator companies must understand what will be needed in ... CMO, has been hosting multiple educational panels and seminars for experts to share ...
(Date:8/30/2015)... , England , August 31, ... beendet die 51-jährige Wartezeit   einer Frau   für ... Frauen im Alter von 7-90   werden ... Programm soll 1200 Frauen behandeln und die ... , Astellas gab heute bekannt, ...
Breaking Biology Technology:New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... Colo., Sept. 25 Steve Pettit, Director of,the ... http://www.InVitria.com ) Cellastim in mammalian cell culture at ... week., "Cellastim showed superior results compared to ... 50% improvement in productivity in CHO cell,lines using ...
... in Complement Inhibition and,Impact of Soliris on Patients ... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) has ... Biotechnology Product for Soliris(R) (eculizumab). The Award,recognizes the ... and the impact the drug is,having on the ...
... Net Income of $27 to $28 ... ... Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), ... China ("PRC"), today announced that it,has increased its revenue and earnings guidance ...
Cached Biology Technology:InVitria's Cellastim Delivers Superior Results in Mammalian Cell Culture 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 2Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 3Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 4Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product 5China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 2China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income 3
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. ... interface solutions, today announced that members of the executive ... the Pacific Crest Global Technology Leadership Forum on Tuesday, ... conference will be held at the Sonnenalp Resort in ... The presentation may include forward-looking information. An audio webcast ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... which trauma and burn patients are most likely to ... range of experimental clinical settings ?an important hurdle to ... rooms and intensive care units. , In a report ... National Academy of Sciences, researchers from eight institutions, including ...
... of California, San Diego (UCSD) have found that Lafora disease, ... the age of 30, can be caused by mutations in ... These findings are reported in the current issue of Proceedings ... is characterized by normal development for the first decade of ...
... comparing, for the first time, breast cancers from Nigeria, ... African ancestry are more likely to be diagnosed with ... of European ancestry. , Researchers from the University of ... in Nigeria and the University of North Carolina, found ...
Cached Biology News:Doctors closer to using gene analysis to help trauma patients 2Doctors closer to using gene analysis to help trauma patients 3UCSD research reveals mechanism involved with type of fatal epilepsy 2Study reveals dramatic difference between breast cancers in US and Africa 2Study reveals dramatic difference between breast cancers in US and Africa 3Study reveals dramatic difference between breast cancers in US and Africa 4
...
... Suite for Mac OS X provides the ... and protein sequence analysis and molecular biology ... (Table 1). With Vector NTI Suite you ... and publicize diverse types of molecular biology ...
...
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Biology Products: